Abstract
We monitored platelet activation by means of P-selectin and platelet monocyte aggregates (PMA) and platelet function by whole blood multiple electrode aggregometry and platelet adhesion under high shear in chronic immune thrombocytopenia patients to define changes in platelet activation during treatment with eltrombopag. Overall, platelet activation and function normalized with increasing platelet counts. However, P-selectin, which was already elevated before treatment, and PMA increased further transiently during the first weeks. The increases in P-selectin and in PMA indicate ongoing platelet activation during the early period of treatment.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Benzoates / pharmacology*
-
Benzoates / therapeutic use*
-
Blood Platelets / drug effects*
-
Blood Platelets / physiology
-
Cell Aggregation / physiology
-
Double-Blind Method
-
Female
-
Humans
-
Hydrazines / pharmacology*
-
Hydrazines / therapeutic use*
-
Male
-
Middle Aged
-
Monocytes / cytology
-
Monocytes / physiology
-
P-Selectin / metabolism
-
Placebos
-
Platelet Activation / drug effects*
-
Platelet Aggregation / physiology
-
Pyrazoles / pharmacology*
-
Pyrazoles / therapeutic use*
-
Thrombocytopenia / blood*
-
Thrombocytopenia / drug therapy*
-
Thrombocytopenia / immunology*
Substances
-
Benzoates
-
Hydrazines
-
P-Selectin
-
Placebos
-
Pyrazoles
-
eltrombopag